Bio Medica Laboratories Ltd
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Bio Medica Laboratories Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
IPO Snapshot
Key metrics and details at a glance.
Price Band
₹139
Per ShareLot Size
1000 Shares
Minimum Investment
₹1,39,000
Issue Size
₹52.43 Cr
Face Value
₹10
Per ShareIPO Type
Book Building - SME
Retail Quota
50.02%
QIB Quota
1%
NII Quota
48.98%
IPO Timeline
Important dates for your applying strategy.
Subscription Status
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Bio Medica Laboratories Ltd
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
96.84%
Promoter Holding (Post-Issue)
67.69%
Issue Type
Book Building - SME
ISIN
INE1BKA01015
About the Company
Our Company is engaged in the manufacturing of Pharmaceutical Parenteral Formulations. We manufacture generic drugs in the form of injectables namely Liquid Injections and Dry Powder Injections. These injectables are available in both single dose and multi dose forms, catering both human and veterinary needs. Our products address a wide range of medical needs and preferences.
Industry Overview
The Indian pharmaceutical industry is the world's 3rd largest by volume of production and known for its generic medicines and low-cost vaccines globally. India is a global leader in the supply of DPT, BCG, and Measles vaccines and one of the largest suppliers of low-cost vaccines in the world. Indian manufacturers account for 60 percent of the vaccine supplies to UNICEF, contributing 40 to 70 percent of the WHO demand for Diphtheria, Tetanus and Pertussis (DPT) and Bacillus Calmette-Guérin (BCG) vaccines, and 90 percent of the WHO demand for the measles vaccine. India has the highest number of United States Food and Drug Administration (USFDA) compliant pharma plants outside of the USA. The pharma sector currently contributes to around 1.72% of the country's GDP. The Indian pharmaceuticals industry is expected to grow 9-11% in the financial year 2024, as per ICRA. Pharmaceutical is one of the top ten attractive sectors for foreign investment in India. The pharmaceutical exports from India reach more than 200 nations around the world, including highly regulated markets of the USA, West Europe, Japan, and Australia. Market size of India pharmaceuticals industry is expected to reach US$ 65 billion by 2024, US$ 130 billion by 2030 and US$ 450 billion market by 2047. According to the government data, the Indian pharmaceutical industry is worth approximately US$ 50 billion with over US$ 25 billion of the value coming from exports. About 20% of the global exports in generic drugs are met by India. The pharmaceutical industry in India is a significant part of the nation's foreign trade and offers lucrative potential for investors. Millions of people around the world receive affordable and inexpensive generic medications from India, which also runs a sizable number of plants that adhere to Good Manufacturing Practice (GMP) standards set by the World Health Organization (WHO) and the United States Food and Drug Administration (USFDA).
Company History
Our Company was originally incorporated as a private limited company with the name of "Bio Medica Laboratories Private Limited" under the Companies Act, 2013 vide certificate of incorporation dated August 14, 2015, issued by Registrar of Companies, Gwalior, bearing CIN U24230MP2015PTC034576. Further, our company was converted into a Public Limited Company in pursuance of a special resolution passed by the members of our Company at the Extra- Ordinary General Meeting held on September 09, 2024 & name of our Company changed from "Bio Medica Laboratories Private Limited" to "Bio Medica Laboratories Limited" & Registrar of Companies, CPC has issued a new certificate of incorporation consequent upon conversion dated October 24, 2024, bearing CIN: U24230MP2015PLC034576.
Growth Strategy
- Expansion and upgradation of our manufacturing facility.
Financial Performance
Revenue, profit after tax and total assets across the last 3 reported financial years.
Revenue
Amount in ₹ crore
Profit After Tax (PAT)
Amount in ₹ crore
Total Assets
Amount in ₹ crore
Figures in ₹ crore, on a standalone basis, as reported for FY23 to FY25.
Objects of the Issue
How the company plans to utilize IPO proceeds.
Use of Proceeds
The funds raised through this IPO will be used for:
Initial public offering of up to 37,72,000 equity shares of Rs.10/- each ("Equity Shares") of Bio Medica Laboratories Limited ("Bio Medica" or "BMLL" or the "Company" or the "Issuer) for cash at a price of Rs. 139 per equity share (the "Issue Price"), aggregating to Rs. 52.43 Crores ("the Issue") comprising a fresh issue of up to 33,95,000 equity shares aggregating to Rs. 47.19 Crores by the company ("Fresh Issue") and an offer for sale of up to 1,88,500 equity shares by Mukesh Mehta and up to 1,88,500 equity shares by Pradeep Mehta ("the Promoter" or "the Selling Shareholder") aggregating to Rs. 2.62 Crores ("Offer for Sale"). Out of the issue, 1,89,000 equity shares aggregating to Rs. 2.63 Crores will be reserved for subscription by market maker ("Market Maker Reservation Portion"). The issue less the market maker reservation portion i.e. Issue of 35,83,000 equity shares of face value of Rs. 10/- each at an issue price of Rs. 139 per equity share aggregating to Rs. 49.80 Crores is hereinafter referred to as the "Net Issue". The issue and the net issue will constitute 30.00% and 28.49%, respectively of the post issue paid up equity share capital of the company. Price Band: Rs. 139/- per equity share of face value Rs. 10/- each. The floor price is 13.90 times the face value of equity shares. Bids can be made for a minimum of 2,000 equity shares and in multiples of 1,000 equity shares thereafter.
*Subject to approvals and market conditions.
Strengths & Risks
Key competitive advantages and factors to consider before investing.
- Designing and execution capabilities.
- Experienced management team and a motivated and efficient work force.
- Cordial relations with our consumers.
- Quality assurance and control.
- The operations in the company Manufacturing Unit-1 had been suspended vide order No. V/T/MISC/20/2023/4790 dated August 23, 2023 by the Deputy Director and State Licensing Authority, Food and Drug Administration, Madhya Pradesh citing certain non-compliances.
- The company is dependent on a limited number of clients for a significant portion of its revenues, and the loss of any key client could adversely affect the company business, financial condition and results of operations.
- Any manufacturing or quality control problems may damage the company reputation for high quality products and expose its to litigation or other liabilities, which could adversely affect the company financial results.
- The Company's manufacturing facilities are subject to inspections by the Central Drugs Standard Control Organisation (CDSCO), the State Licensing Authorities, and other competent regulatory bodies. Any adverse findings or non-compliance may result in regulatory actions that could adversely affect the Company's business, operations, and financial performance
- The company is dependent on third-party transportation providers for the supply of raw materials and finished products